SMI
|
11 942,05
|
24,46
|
0,21%
|
Analysen zu SMI-Werten
| 12.01.24 | Richemont Buy | Deutsche Bank AG | |
| 12.01.24 | Richemont Buy | Jefferies & Company Inc. | |
| 12.01.24 | Swiss Re Overweight | JP Morgan Chase & Co. | |
| 12.01.24 | Richemont Sector Perform | RBC Capital Markets | |
| 11.01.24 | UBS Outperform | RBC Capital Markets | |
| 11.01.24 | Richemont Buy | Goldman Sachs Group Inc. | |
| 11.01.24 | Richemont Overweight | JP Morgan Chase & Co. | |
| 11.01.24 | Roche Underweight | JP Morgan Chase & Co. | |
| 11.01.24 | Givaudan Underperform | Jefferies & Company Inc. | |
| 10.01.24 | Swiss Re Sector Perform | RBC Capital Markets | |
| 10.01.24 | Givaudan Neutral | JP Morgan Chase & Co. | |
| 10.01.24 | Nestlé Overweight | JP Morgan Chase & Co. | |
| 10.01.24 | Holcim Neutral | Merrill Lynch & Co., Inc. | |
| 10.01.24 | Zurich Insurance Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 10.01.24 | Givaudan Market-Perform | Bernstein Research | |
| 09.01.24 | ABB Hold | Jefferies & Company Inc. | |
| 09.01.24 | Roche Equal Weight | Barclays Capital | |
| 09.01.24 | Novartis Neutral | JP Morgan Chase & Co. | |
| 09.01.24 | Givaudan Market-Perform | Bernstein Research | |
| 08.01.24 | Novartis Neutral | JP Morgan Chase & Co. | |
| 08.01.24 | Novartis Neutral | UBS AG | |
| 08.01.24 | Richemont Sector Perform | RBC Capital Markets | |
| 05.01.24 | UBS Outperform | RBC Capital Markets | |
| 05.01.24 | Novartis Buy | Deutsche Bank AG | |
| 04.01.24 | Swiss Re Sector Perform | RBC Capital Markets | |
| 04.01.24 | ABB Market-Perform | Bernstein Research | |
| 03.01.24 | Novartis Neutral | JP Morgan Chase & Co. | |
| 03.01.24 | Richemont Buy | UBS AG | |
| 03.01.24 | Novartis Buy | Jefferies & Company Inc. | |
| 03.01.24 | Roche Hold | Jefferies & Company Inc. | |
| 02.01.24 | Richemont Outperform | Bernstein Research | |
| 02.01.24 | ABB Neutral | JP Morgan Chase & Co. | |
| 02.01.24 | Roche Underweight | JP Morgan Chase & Co. | |
| 28.12.23 | Nestlé Market-Perform | Bernstein Research | |
| 21.12.23 | Novartis Underweight | Barclays Capital | |
| 20.12.23 | UBS Outperform | RBC Capital Markets | |
| 19.12.23 | Richemont Overweight | Barclays Capital | |
| 19.12.23 | Nestlé Overweight | Barclays Capital | |
| 19.12.23 | Givaudan Underweight | Barclays Capital | |
| 19.12.23 | Givaudan Hold | Deutsche Bank AG |
Analysen zu Aktien folgender Indizes
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.